24
Treatment Advances in Achieving Remission in Mild to Moderate Ulcerative Colitis

Treatment Advances in Achieving Remission in Mild to Moderate Ulcerative Colitis

Embed Size (px)

DESCRIPTION

Treatment Advances in Achieving Remission in Mild to Moderate Ulcerative Colitis. Goals of Therapy for Patients With UC. Sequential Therapies for UC. Oral 5-ASA Formulations: Sites of Delivery. Conventional Corticosteroids in UC. Corticosteroids: Dependency — Short- and Long-term Efficacy. - PowerPoint PPT Presentation

Citation preview

Page 1: Treatment Advances in Achieving Remission in Mild to Moderate Ulcerative Colitis

Treatment Advances in Achieving Remission in Mild to

Moderate Ulcerative Colitis

Page 2: Treatment Advances in Achieving Remission in Mild to Moderate Ulcerative Colitis

Goals of Therapy for Patients With UC

Page 3: Treatment Advances in Achieving Remission in Mild to Moderate Ulcerative Colitis

Sequential Therapies for UC

Page 4: Treatment Advances in Achieving Remission in Mild to Moderate Ulcerative Colitis

Oral 5-ASA Formulations: Sites of Delivery

Page 5: Treatment Advances in Achieving Remission in Mild to Moderate Ulcerative Colitis

Conventional Corticosteroids in UC

Page 6: Treatment Advances in Achieving Remission in Mild to Moderate Ulcerative Colitis

Corticosteroids: Dependency—Short- and Long-term Efficacy

Page 7: Treatment Advances in Achieving Remission in Mild to Moderate Ulcerative Colitis

CORE I and II: Budesonide MMX Primary End Point: Combined Clinical and Endoscopic

Remission

Page 8: Treatment Advances in Achieving Remission in Mild to Moderate Ulcerative Colitis

Azathioprine vs 5-ASA for Corticosteroid-Dependent, Active

UC

Page 9: Treatment Advances in Achieving Remission in Mild to Moderate Ulcerative Colitis

Anti-TNF Therapies for Moderate to Severe Disease

Page 10: Treatment Advances in Achieving Remission in Mild to Moderate Ulcerative Colitis

Treatment Algorithm to Maximize Remission and Minimize

Corticosteroid Dependence in UC

Page 11: Treatment Advances in Achieving Remission in Mild to Moderate Ulcerative Colitis

Patient Case

Page 12: Treatment Advances in Achieving Remission in Mild to Moderate Ulcerative Colitis

Mesalamine Safety

Page 13: Treatment Advances in Achieving Remission in Mild to Moderate Ulcerative Colitis

Patient Case (cont)

Page 14: Treatment Advances in Achieving Remission in Mild to Moderate Ulcerative Colitis

Pooled Safety Data: Adverse Effects of Budesonide MMX in Patients With Active UC

Page 15: Treatment Advances in Achieving Remission in Mild to Moderate Ulcerative Colitis

Anti-TNF Agents: Adverse Events

Page 16: Treatment Advances in Achieving Remission in Mild to Moderate Ulcerative Colitis

Minimizing Toxicity for Anti-TNF Therapy

Page 17: Treatment Advances in Achieving Remission in Mild to Moderate Ulcerative Colitis

Summary: Safety

Page 18: Treatment Advances in Achieving Remission in Mild to Moderate Ulcerative Colitis

Effect on Bone Density

Page 19: Treatment Advances in Achieving Remission in Mild to Moderate Ulcerative Colitis

Monitoring the Patient Receiving Budesonide MMX

Page 20: Treatment Advances in Achieving Remission in Mild to Moderate Ulcerative Colitis

Summary: Safety of Agents Used to Induce Remission in Mild to

Moderate UC

Page 21: Treatment Advances in Achieving Remission in Mild to Moderate Ulcerative Colitis

Abbreviations

Page 22: Treatment Advances in Achieving Remission in Mild to Moderate Ulcerative Colitis

References

Page 23: Treatment Advances in Achieving Remission in Mild to Moderate Ulcerative Colitis

References (cont)

Page 24: Treatment Advances in Achieving Remission in Mild to Moderate Ulcerative Colitis

References (cont)